F9 (Coagulation Factor IX / Christmas Factor Serine Protease Gene)
F9 (coagulation factor IX; HGNC:3551, NCBI Gene ID 2158) is a human locus mapped to chromosome band Xq27.1 that encodes vitamin K-dependent serine protease zymogen Factor IX (415 mature aa; EC 3.4.21.22). F9 acts in intrinsic coagulation tenase protease activating Factor X in complex with Factor VIIIa, together with F8 (Coagulation Factor VIII Gene), F2 (Prothrombin / Thrombin Gene), and F5 (Coagulation Factor V Gene). Encodes vitamin K-dependent coagulation factor IX; mutated in hemophilia B and delivered as the hyperactive Padua variant in AAV5 gene therapy.
Genomic Organization & Cytogenetic Locus: 8-exon gene spanning 33.5 kb on chromosome Xq27.1, encoding a 461-residue preproprotein featuring an N-terminal gamma-carboxyglutamic acid (Gla) domain (12 Glu residues carboxylated by GGCX), two EGF-like domains, an activation peptide, and a C-terminal trypsin-like serine protease catalytic domain.
Cellular & Tissue Expression Profile: Synthesized exclusively by hepatic hepatocytes and secreted into plasma as a 57 kDa single-chain zymogen after vitamin K-dependent gamma-carboxylation in the endoplasmic reticulum.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Activated by tissue factor-Factor VIIa or Factor XIa via cleavage of the Arg145-Ala146 and Arg180-Val181 bonds to release the activation peptide; active Factor IXa then complexes via its Gla domain with Ca2+, platelet membrane phospholipids, and cofactor Factor VIIIa (F8) to cleave Factor X into Factor Xa.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Hemizygous loss-of-function mutations cause X-linked recessive Hemophilia B (Christmas disease, ~1 in 25,000 male births), including rare promoter mutations in the HNF4alpha/AR element that cause Hemophilia B Leyden (which spontaneously resolves at male puberty under androgen receptor stimulation); conversely, the naturally occurring missense variant Factor IX-Padua (p.Arg338Leu) confers an 8- to 9-fold increase in specific catalytic activity.
Therapeutic & Clinical Pharmacology: Harnessing the hyperactive Padua (p.Arg338Leu) variant enabled low-dose hepatic AAV gene delivery to achieve near-normal clotting activity, culminating in FDA approval of AAV5-hFIXco-Padua (etranacogene dezaparvovec / Hemgenix) for adult Hemophilia B.